CLINICAL TRIALS PROFILE FOR MICAFUNGIN

505(b)(2) Clinical Trials for MICAFUNGIN

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Institutul Clinic Fundeni	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Institutul Clinic Fundeni Bucharest	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Universitaire Ziekenhuizen Leuven	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.

All Clinical Trials for MICAFUNGIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00047827 ↗	Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis	Terminated	Astellas Pharma Inc	Phase 2	2002-12-01	The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
NCT00048750 ↗	Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU	Terminated	Astellas Pharma Inc	Phase 3	2003-01-01	The purpose of this study is to determine the efficacy and safety of intravenous micafungin versus placebo as prophylactic therapy for invasive fungal infections in patients in the intensive care unit considered to be at high risk.
NCT00105144 ↗	Study of Micafungin in Patients With Invasive Candidiasis or Candidemia	Completed	Astellas Pharma Inc	Phase 3	2004-09-01	The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
NCT00106288 ↗	Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia	Completed	Astellas Pharma Inc	Phase 3	2003-01-01	The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or candidemia. Enrollment will include adult and pediatric patients.
NCT00189709 ↗	Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia	Completed	Astellas Pharma Taiwan, Inc.	Phase 3	2004-08-01	To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia
NCT00189709 ↗	Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia	Completed	Astellas Pharma Inc	Phase 3	2004-08-01	To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia

Clinical Trial Conditions for MICAFUNGIN

Condition Name

Condition Name for MICAFUNGIN
Intervention	Trials
Candidemia	8
Candidiasis	7
Invasive Candidiasis	7
Aspergillosis	3

Condition MeSH

Condition MeSH for MICAFUNGIN
Intervention	Trials
Candidiasis	21
Mycoses	20
Candidiasis, Invasive	14
Invasive Fungal Infections	12

Clinical Trial Locations for MICAFUNGIN

Trials by Country

Trials by Country for MICAFUNGIN
Location	Trials
United States	183
Canada	22
Brazil	12
Spain	10
France	10

Trials by US State

Trials by US State for MICAFUNGIN
Location	Trials
Texas	13
North Carolina	12
California	11
Pennsylvania	8
New York	8

Clinical Trial Progress for MICAFUNGIN

Clinical Trial Phase

Clinical Trial Phase for MICAFUNGIN
Clinical Trial Phase	Trials
PHASE4	2
Phase 4	18
Phase 3	12

Clinical Trial Status

Clinical Trial Status for MICAFUNGIN
Clinical Trial Phase	Trials
Completed	36
Terminated	12
Unknown status	4

Clinical Trial Sponsors for MICAFUNGIN

Sponsor Name

Sponsor Name for MICAFUNGIN
Sponsor	Trials
Astellas Pharma Inc	20
Astellas Pharma China, Inc.	4
Astellas Pharma US, Inc.	3

Sponsor Type

Sponsor Type for MICAFUNGIN
Sponsor	Trials
Industry	38
Other	37
NIH	4

MICAFUNGIN Market Analysis and Financial Projection

Last updated: February 11, 2026

What is the current status of clinical trials for Micafungin?

Micafungin, an echinocandin antifungal agent, is approved by regulatory agencies such as the FDA for invasive candidiasis and esophageal candidiasis. Its clinical development continues in various areas, including pediatric indications, prophylaxis in hematopoietic stem cell transplant (HSCT) patients, and resistant Candida infections.

As of 2023, key ongoing clinical trials include:

• Pediatric indications: Phase IV post-marketing surveillance evaluating safety and efficacy in pediatric populations. These trials aim for expanded labeling and better understanding of dosing in children.
• Prophylactic use in HSCT: A randomized, controlled trial (NCT04985215) assessed Micafungin as prophylaxis to prevent invasive fungal infections in HSCT patients. Results have yet to be published.
• Treatment of resistant Candida species: Trials evaluate efficacy against multidrug-resistant strains. These studies are mostly early-phase, with some Phase II trials ongoing across North America and Europe.

No new large-scale Phase III trials are currently recruiting outside approved indications. The existing data support ongoing expansion and post-marketing research.

What is the market size for Micafungin and similar antifungal agents?

The global antifungal drugs market was valued at approximately $13 billion in 2022. Micafungin contributes a significant share, particularly in hospital settings treating invasive fungal infections.

Key market drivers:

• Rising invasive fungal infections: Increased prevalence in immunocompromised populations, notably cancer, transplant, and HIV patients.
• Limited antifungal options: Resistance to azoles and amphotericin B drives demand for echinocandins like Micafungin.
• Growing healthcare expenditure: Higher spending on fungal infection management contributes to market growth.

Market segments include:

Segment	Market Share (2022)	Growth Rate (CAGR 2022-2027)
Echinocandins (incl. Micafungin)	45%	7%
Azoles	40%	4%
Amphotericin B	15%	2%

Micafungin's market share is estimated at 20-25% within echinocandins, with caspofungin and anidulafungin as primary competitors. North America dominates, accounting for over 50% of the market, followed by Europe and Asia-Pacific.

How does Micafungin compare to competing antifungal agents?

The primary competitors for Micafungin are:

• Caspofungin: More widely approved; similar efficacy profile but slightly more extensive formulary coverage.
• Anidulafungin: Has a longer half-life facilitating less frequent dosing.
• Azoles: Usually oral, less invasive, but face increasing resistance.
• Amphotericin B: Broad spectrum but higher toxicity.

Therapeutic differences:

Feature	Micafungin	Caspofungin	Anidulafungin	Azoles
Approved indications	Candidate for invasive candidiasis	Invasive candidiasis, candida bloodstream infections	Same as caspofungin	Broad antifungal spectrum
Dosing frequency	Once daily	Once daily	Once daily	Daily (oral/IV)
Toxicity profile	Lower hepatotoxicity	Slightly higher hepatotoxicity	Minimal toxicity	Variable, resistance concerns
Resistance issues	Minimal reported resistance	Emerging resistance in some strains	Limited data	Rising resistance in some fungi

Market selection depends on efficacy, resistance profile, toxicity, and dosing convenience.

What are the projections for Micafungin's market growth?

The antifungal market is expected to grow at a CAGR of approximately 6-7% through 2027. Factors influencing Micafungin's growth include:

• Expansion into pediatric and prophylaxis markets: Trials and regulatory approvals expected to increase usage.
• New formulations: Investigational oral formulations could increase outpatient use.
• Market penetration in emerging economies: Access improvements and generic options may lower costs.
• Resistance-driven demand: Ongoing resistance concerns may favor echinocandin use.

Projections estimate Micafungin's global sales revenue could reach $1.4-1.6 billion by 2027, representing over 20% growth from 2022 levels.

What are the regulatory and patent landscape dynamics?

Micafungin's patent has expired in many jurisdictions, with generic versions available since 2020 in the US and Europe. Patents in Asia remain in force until 2024-2026.

Regulatory pathways for new indications or formulations are advancing:

• FDA: Post-marketing surveillance and supplemental NDAs to expand indications.
• EMA: Similar pathways for approval in Europe.
• Parallel importation and pricing policies in emerging markets may influence sales.

Key Takeaways

• The clinical trial landscape for Micafungin focuses on pediatric safety, prophylaxis, and resistant strains, with no major Phase III trials currently underway.
• The global antifungal market, particularly for echinocandins, shows steady growth driven by rising infections, resistance, and healthcare expenditure.
• Micafungin competes primarily with caspofungin and anidulafungin, differing mainly in dosing and toxicity profiles.
• Market projections suggest sustained growth, with revenues reaching $1.6 billion by 2027.
• Patent expirations open opportunities for generics; regulatory efforts are aimed at expanding its use.

FAQs

1. When was Micafungin first approved?
Approved by the FDA in 2005 for invasive candidiasis and esophageal candidiasis.

2. Are there any new formulations of Micafungin?
Research into oral formulations exists, but none have received regulatory approval as of 2023.

3. How resistant are fungi to Micafungin?
Resistance remains rare but is emerging in some Candida glabrata strains.

4. What are the main side effects of Micafungin?
Generally well tolerated; possible side effects include liver enzyme elevation and headache.

5. How does pricing compare across regions?
Pricing varies; generic versions have decreased costs in North America and Europe, while costs remain higher in emerging markets.

---

References

[1] MarketsandMarkets. "Antifungal drugs market by type." 2022.
[2] ClinicalTrials.gov. "Micafungin trials." 2023.
[3] FDA. Drug approval history for Micafungin. 2005.
[4] IQVIA. "Global antifungal market analysis." 2022.